Actively Recruiting
Phase IIa Trial to Test Safety and Effectiveness of Intravenous hUC-MSCs for Treating Acute Ischemic Stroke in Adults
Led by Shenzhen Wingor Biotechnology Co., Ltd. · Updated on 2026-07-29
60
Participants Needed
1
Research Sites
82 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on patients with acute ischemic stroke AIS, a leading cause of death and disability worldwide. It evaluates the effectiveness and safety of intravenous infusions of human umbilical cord mesenchymal stem cells hUC-MSCs in treating AIS. The study uses a randomized, double-blind, placebo-controlled design to assess single and multiple stem cell infusions in improving stroke outcomes. Participants are divided into three groups one receiving a high dose single infusion of hUC-MSCs followed by placebo infusions, another receiving three low-dose hUC-MSC infusions, and a third receiving three placebo infusions. Infusions are administered on Day 0, Day 7 2 days, and Day 14 2 days. The trial compares these groups to evaluate efficacy, safety, and the behavior of the stem cells in the body. During the study, participants undergo various assessments including neurological scales like the modified Rankin Scale, NIH Stroke Scale, Barthel Index, and motor function evaluations at multiple follow-up points up to 360 days. Researchers monitor adverse events, mortality, and changes in stroke severity and motor function. The total study duration allows for comprehensive evaluation of both short-term and long-term effects and safety of the treatment.
CONDITIONS
Brief Title
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
Research Team
X
XiaohongWang,MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here